Status:
COMPLETED
Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity
Lead Sponsor:
University of Colorado, Boulder
Collaborating Sponsors:
University of Colorado, Denver
Conditions:
Type 2 Diabetes
Obesity
Eligibility:
All Genders
21-40 years
Brief Summary
This study tests the effects of cannabinoid levels in blood on inflammation and insulin sensitivity both acutely and chronically in individuals across the weight spectrum. To that end, the study emplo...
Detailed Description
According to the National Institute of Diabetes and Digestive and Kidney Diseases, over 30 million people in the US have diabetes, and just over 84 million people have pre-diabetes. Concurrently, 30 s...
Eligibility Criteria
Inclusion
- Able to provide informed consent
- Cannabis users in Study A must have smoked or vaped cannabis at least once since January 1st 2014 with no negative effects but NOT used in the past three months
- Cannabis users in Study B must have been a regular (at least weekly) user for at least a year
- Non-users in Study B cannot have used any cannabis in the previous year
- Weight stable (\<5 pound fluctuation in the past six months)
- Planning to remain in the Boulder-Denver area for the next month
- Fasting blood glucose greater than or equal to 55 mg/dl and less than or equal to 126 mg/dl
- Cannabis users in Study A must endorse knowledge of the procedure(s) for smoking or vaping cannabis
Exclusion
- Known auto-immune disease
- Report of other drug use (cocaine, opiates, methamphetamine) in the past 90 days or fail urine screen for any of these drugs
- Daily tobacco (cigarette, E-cigs, smokeless) user, given the impact of tobacco smoking on insulin function
- Blood alcohol level greater than 0 at screening
- Current use of medications for glucose lowering, immunosuppression, or anti-inflammation
- Acute illness
- Current use of psychotropic medications
- Current diagnosis of diabetes
- Heavy drinking as defined by an Alcohol Use Disorders Test (AUDIT)
- Females can not be pregnant or trying to become pregnant
- Females can not be nursing mothers
- Have donated blood in the 8 weeks before the study or intend to donate blood in the 8 weeks after the study.
Key Trial Info
Start Date :
November 8 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2024
Estimated Enrollment :
255 Patients enrolled
Trial Details
Trial ID
NCT04114903
Start Date
November 8 2019
End Date
December 1 2024
Last Update
December 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Innovation and Creativity
Boulder, Colorado, United States, 80301